Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...

Lexicon Pharmaceuticals (LXRX) announced the publication of preclinical data validating Acyl-CoA Synthetase 5 as a target for obesity and chronic ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

A glimmer of hope for Alzheimer’s patients vanished Monday, when Novo Nordisk said a trial of an oral version of its weight loss drug Wegovy didn’t slow the progression of the disease in two large, ...

Novo Nordisk filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish drugmaker submitted an application for Wegovy 7.2 ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...